Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07591077 Empagliflozin Diabetes Mellitus, Type 1 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07591077 clinical trial report covering Empagliflozin, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07611019 Colchicine Atrial Fibrillation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07611019 clinical trial report covering Colchicine, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07509307 Zenagamtide Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07509307 clinical trial report covering Zenagamtide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07585396 Inositol Polyendocrine Metabolic Ovarian Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07585396 clinical trial report covering Inositol, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07509645 Tocilizumab Infarction, Posterior Cerebral Artery Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07509645 clinical trial report covering Tocilizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07509151 Surovatamig Chronic Lymphocytic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07509151 clinical trial report covering Surovatamig, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07511127 Maribavir Cytomegalovirus viremia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07511127 clinical trial report covering Maribavir, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07510945 Ciprofol Anesthesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07510945 clinical trial report covering Ciprofol, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07512960 Clopidogrel Bisulfate Chronic Limb-Threatening Ischemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07512960 clinical trial report covering Clopidogrel Bisulfate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07511647 QL2106 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07511647 clinical trial report covering QL2106, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07511543 Semaglutide (Novo Nordisk) occlusions Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07511543 clinical trial report covering Semaglutide (Novo Nordisk), Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07515079 Recombinant humanized anti-VEGF monoclonal antibody(Bio-Thera Solutions) Diabetic macular oedema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07515079 clinical trial report covering Recombinant humanized anti-VEGF monoclonal antibody(Bio-Thera Solutions), Phase 3, endpoints, sponsor, geography